106. クリオピリン関連周期熱症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 42 / 薬物数 : 24 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 48
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
ACZ885
NOVARTIS FARMA
2008 - EUCTR2007-004367-22-IT France;Germany;Italy;Spain;United Kingdom;
Novartis Farmacéutica S.A
2012 - EUCTR2011-005154-57-ES Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
Novartis Pharma Services AG
2013 Phase 3 EUCTR2011-005154-57-GB Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
2013 Phase 3 EUCTR2009-016859-22-FR Belgium;France;Germany;Ireland;Spain;United Kingdom;
2013 - EUCTR2011-005154-57-FR Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-005154-57-BE Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
2012 - EUCTR2011-005154-57-DE Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-016859-22-GB Belgium;France;Germany;Ireland;Spain;United Kingdom;
2010 - EUCTR2009-016859-22-BE Belgium;France;Germany;Spain;United Kingdom;
2009 - EUCTR2007-004367-22-BE Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004367-22-GB Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-FR Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-DE France;Germany;Italy;Spain;United Kingdom;
- Phase 3 EUCTR2009-016859-22-IE Belgium;Canada;France;Germany;Ireland;Israel;Spain;Switzerland;United Kingdom;
- - EUCTR2009-016859-22-Outside-EU/EEA Canada;Israel;Switzerland;
- - EUCTR2008-001429-32-Outside-EU/EEA United States;
- - EUCTR2007-004367-22-Outside-EU/EEA India;Turkey;United States;
Novartis Pharmaceuticals
2012 Phase 3 NCT01576367 Belgium;Canada;France;Germany;Spain;Switzerland;United Kingdom;
2010 Phase 3 NCT01302860 Belgium;Canada;France;Germany;Spain;Switzerland;United Kingdom;
- - EUCTR2015-003491-69-Outside-EU/EEA Canada;
- - EUCTR2015-003490-15-Outside-EU/EEA Japan;
ACZ885 drug substance
Novartis Pharma Services AG
2007 - EUCTR2004-002980-26-FR France;Germany;Spain;United Kingdom;
ATI-450
Aclaris Therapeutics, Inc.
2020 Phase 2 NCT04524858 United States;
Anakinra
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2003 Phase 1/Phase 2 NCT00069329 United States;
Anti-interleukin-1B monoclonal antibody
NOVARTIS FARMA
2008 - EUCTR2007-004367-22-IT France;Germany;Italy;Spain;United Kingdom;
C-028380
Inflazome (Australia) Pty Ltd.
2020 Phase 2 EUCTR2020-000489-40-GB Australia;Ireland;United Kingdom;
Canakinumab
Novartis Pharmaceuticals
2009 Phase 3 NCT00991146 Japan;
2009 Phase 3 NCT00770601 United States;
Canakinumab (ACZ885)
Novartis
2008 Phase 3 NCT00685373 Belgium;France;Germany;India;Italy;Spain;Turkey;United Kingdom;United States;
Canakinumab (WHO approval pending)
Novartis Pharma Services AG
2009 - EUCTR2007-004367-22-BE Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004367-22-GB Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-FR Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-DE France;Germany;Italy;Spain;United Kingdom;
Canakinumab (company code: ACZ885D)
Novartis Pharmaceuticals
2010 Phase 3 NCT01105507 Canada;
DFV890
NOVARTIS PHARMA AG
2021 Phase 1;Phase 2 EUCTR2020-005948-33-IT Germany;Italy;United States;
Novartis Pharma AG
2021 Phase 2 EUCTR2020-005948-33-DE Germany;Italy;United States;
Novartis Pharmaceuticals
2021 Phase 2 NCT04868968 Germany;Italy;United States;
IZD174
Inflazome (Australia) Pty Ltd.
2020 Phase 2 EUCTR2020-000489-40-GB Australia;Ireland;United Kingdom;
IZD334
Inflazome UK Ltd
2019 Phase 1 NCT04086602 Australia;
Ilaris
Novartis Pharmaceuticals
- - EUCTR2015-003491-69-Outside-EU/EEA Canada;
- - EUCTR2015-003490-15-Outside-EU/EEA Japan;
UZ Leuven
2014 - EUCTR2014-001393-34-BE Belgium;
Inzomelid
Inflazome (Australia) Pty Ltd.
2020 Phase 2 EUCTR2020-000489-40-GB Australia;Ireland;United Kingdom;
Kineret
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- - EUCTR2013-000300-42-Outside-EU/EEA United States;
Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class
Novartis Pharma Services AG
2013 Phase 3 EUCTR2009-016859-22-FR Belgium;France;Germany;Ireland;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-016859-22-GB Belgium;France;Germany;Ireland;Spain;United Kingdom;
2010 - EUCTR2009-016859-22-DE Belgium;France;Germany;Spain;United Kingdom;
2010 - EUCTR2009-016859-22-BE Belgium;France;Germany;Spain;United Kingdom;
Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class
Novartis Pharma Services AG
2009 - EUCTR2007-004367-22-BE Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004367-22-GB Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-FR Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-DE France;Germany;Italy;Spain;United Kingdom;
Rilonacept
Charite University, Berlin, Germany
2009 Phase 2 NCT01045772 Germany;
Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
2008 - EUCTR2006-004290-97-DE Germany;
Regeneron Pharmaceuticals
2005 Phase 3 NCT00288704 United States;
Tranilast
Peking Union Medical College Hospital
2019 Phase 2 NCT03923140 China;
XOMA 052
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2010 Phase 1/Phase 2 NCT01211977 United States;
NOVARTIS FARMA
2008 - EUCTR2007-004367-22-IT France;Germany;Italy;Spain;United Kingdom;
Novartis Farmacéutica S.A
2012 - EUCTR2011-005154-57-ES Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
Novartis Pharma Services AG
2013 Phase 3 EUCTR2011-005154-57-GB Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
2013 Phase 3 EUCTR2009-016859-22-FR Belgium;France;Germany;Ireland;Spain;United Kingdom;
2013 - EUCTR2011-005154-57-FR Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-005154-57-BE Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
2012 - EUCTR2011-005154-57-DE Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-016859-22-GB Belgium;France;Germany;Ireland;Spain;United Kingdom;
2010 - EUCTR2009-016859-22-BE Belgium;France;Germany;Spain;United Kingdom;
2009 - EUCTR2007-004367-22-BE Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004367-22-GB Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-FR Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-DE France;Germany;Italy;Spain;United Kingdom;
- Phase 3 EUCTR2009-016859-22-IE Belgium;Canada;France;Germany;Ireland;Israel;Spain;Switzerland;United Kingdom;
- - EUCTR2009-016859-22-Outside-EU/EEA Canada;Israel;Switzerland;
- - EUCTR2008-001429-32-Outside-EU/EEA United States;
- - EUCTR2007-004367-22-Outside-EU/EEA India;Turkey;United States;
Novartis Pharmaceuticals
2012 Phase 3 NCT01576367 Belgium;Canada;France;Germany;Spain;Switzerland;United Kingdom;
2010 Phase 3 NCT01302860 Belgium;Canada;France;Germany;Spain;Switzerland;United Kingdom;
- - EUCTR2015-003491-69-Outside-EU/EEA Canada;
- - EUCTR2015-003490-15-Outside-EU/EEA Japan;
ACZ885 drug substance
Novartis Pharma Services AG
2007 - EUCTR2004-002980-26-FR France;Germany;Spain;United Kingdom;
ATI-450
Aclaris Therapeutics, Inc.
2020 Phase 2 NCT04524858 United States;
Anakinra
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2003 Phase 1/Phase 2 NCT00069329 United States;
Anti-interleukin-1B monoclonal antibody
NOVARTIS FARMA
2008 - EUCTR2007-004367-22-IT France;Germany;Italy;Spain;United Kingdom;
C-028380
Inflazome (Australia) Pty Ltd.
2020 Phase 2 EUCTR2020-000489-40-GB Australia;Ireland;United Kingdom;
Canakinumab
Novartis Pharmaceuticals
2009 Phase 3 NCT00991146 Japan;
2009 Phase 3 NCT00770601 United States;
Canakinumab (ACZ885)
Novartis
2008 Phase 3 NCT00685373 Belgium;France;Germany;India;Italy;Spain;Turkey;United Kingdom;United States;
Canakinumab (WHO approval pending)
Novartis Pharma Services AG
2009 - EUCTR2007-004367-22-BE Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004367-22-GB Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-FR Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-DE France;Germany;Italy;Spain;United Kingdom;
Canakinumab (company code: ACZ885D)
Novartis Pharmaceuticals
2010 Phase 3 NCT01105507 Canada;
DFV890
NOVARTIS PHARMA AG
2021 Phase 1;Phase 2 EUCTR2020-005948-33-IT Germany;Italy;United States;
Novartis Pharma AG
2021 Phase 2 EUCTR2020-005948-33-DE Germany;Italy;United States;
Novartis Pharmaceuticals
2021 Phase 2 NCT04868968 Germany;Italy;United States;
IZD174
Inflazome (Australia) Pty Ltd.
2020 Phase 2 EUCTR2020-000489-40-GB Australia;Ireland;United Kingdom;
IZD334
Inflazome UK Ltd
2019 Phase 1 NCT04086602 Australia;
Ilaris
Novartis Pharmaceuticals
- - EUCTR2015-003491-69-Outside-EU/EEA Canada;
- - EUCTR2015-003490-15-Outside-EU/EEA Japan;
UZ Leuven
2014 - EUCTR2014-001393-34-BE Belgium;
Inzomelid
Inflazome (Australia) Pty Ltd.
2020 Phase 2 EUCTR2020-000489-40-GB Australia;Ireland;United Kingdom;
Kineret
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- - EUCTR2013-000300-42-Outside-EU/EEA United States;
Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class
Novartis Pharma Services AG
2013 Phase 3 EUCTR2009-016859-22-FR Belgium;France;Germany;Ireland;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-016859-22-GB Belgium;France;Germany;Ireland;Spain;United Kingdom;
2010 - EUCTR2009-016859-22-DE Belgium;France;Germany;Spain;United Kingdom;
2010 - EUCTR2009-016859-22-BE Belgium;France;Germany;Spain;United Kingdom;
Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class
Novartis Pharma Services AG
2009 - EUCTR2007-004367-22-BE Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004367-22-GB Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-FR Belgium;France;Germany;Italy;Spain;United Kingdom;
2008 - EUCTR2007-004367-22-DE France;Germany;Italy;Spain;United Kingdom;
Rilonacept
Charite University, Berlin, Germany
2009 Phase 2 NCT01045772 Germany;
Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
2008 - EUCTR2006-004290-97-DE Germany;
Regeneron Pharmaceuticals
2005 Phase 3 NCT00288704 United States;
Tranilast
Peking Union Medical College Hospital
2019 Phase 2 NCT03923140 China;
XOMA 052
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2010 Phase 1/Phase 2 NCT01211977 United States;